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after hysterectomy with or without bilateral oophorectomy with the changes observed up to and after natural
menopause.Background Evidence suggests that hysterectomy status with or without bilateral oophorectomy might increase risk for CVD, but
most studies retrospectively assess menopausal status.Methods Study of Women’s Health across the Nation enrolled 3,302 pre-menopausal women not using hormone therapy
between 42 and 52 years of age and followed them annually for over 11 years for sociodemographic characteristics,
menopausal status, surgeries, body mass index, medication use, lifestyle factors, lipids, blood pressure, insulin
resistance, and hemostatic and inﬂammatory factors. By 2008, 1,769 women had reached natural menopause,
77 women had a hysterectomy with ovarian conservation, and 106 women had a hysterectomy with bilateral
oophorectomy. Piece-wise hierarchical growth models compared these groups on annual changes in CVD risk
factors before and after ﬁnal menstrual period or surgery.Results Multivariable analyses showed that annual changes in CVD risk factors did not vary by group, with few exceptions,
and the signiﬁcant group differences that did emerge were not in the anticipated direction.Conclusions Hysterectomy with or without ovarian conservation is not a key determinant of CVD risk factor status either before
or after elective surgery in midlife. These results should provide reassurance to women and their clinicians that
hysterectomy in midlife is unlikely to accelerate the CVD risk of women. (J Am Coll Cardiol 2013;62:191–200)
ª 2013 by the American College of Cardiology FoundationElective hysterectomy is a common surgical procedure to
improve quality of life among symptomatic women
approaching menopause (1–3). The clear beneﬁts of surgery
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13; revised manuscript received April 4, 2013,cardiovascular disease (CVD). The cardiovascular risk asso-
ciated with hysterectomy, especially accompanied by bilateral
oophorectomy, is not yet clear. In the Framingham Heart
Study, women who had a hysterectomy, especially with
bilateral oophorectomy, were later at elevated risk for CVD,
adjusting for age group and smoking status (4). In the
Nurse’s Health Study, women who had a bilateral oopho-
rectomy, usually occurring in the ﬁfth decade, were at greater
risk for incident coronary heart disease and total mortality
than women who had a hysterectomy without oophorectomy
(5). By contrast, in a large registry of Swedish women, the
risk for incident coronary heart disease, stroke, and heart
failure during the follow-up was not conﬁned to women
with hysterectomy accompanied by bilateral oophorectomy;
both surgical groups were at elevated risk (6). However,
this relationship was only observed among women 50 years
of age or less, and smoking was not statistically controlled.
In an older cohort of women enrolled in the Women’s
Health Initiative, women with bilateral oophorectomy and
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192hysterectomy did not have a
greater incidence of CVD, ad-
justing for a large number of
CVD risk factors (7), compared
with women with hysterectomy
alonedsimilar to the results from
the Swedish registry. In the same
study, women who had hysterec-
tomy regardless of ovarian con-
servation had elevated levels of
CVD risk factors and were
more often diabetic and hyper-
tensive (8), compared with post-
menopausal women who had not
had a hysterectomy. Furthermore,
hysterectomy, regardless of ovar-
ian conservation, was associated
with incident CVD, with associa-
tions largely attenuated after
introducing a wide array of car-
diovascular risk factors and socio-
demographic characteristics.
Taken together, the ﬁndingsraise a number of important issues. Because these studies
only assessed CVD risk factors years after hysterectomy and/
or oophorectomy, without assessment of pre-surgery CVD
risk-factor levels, it is unknown whether elevated CVD risk
led to the conditions warranting a surgical menopause or
whether CVD risk was accelerated post-surgery. For
example, obesity in pre-menopausal women increases the
likelihood of abnormal bleeding and ﬁbroids, which are
common indications for these gynecologic surgeries (9–12).
It is also not clear whether hysterectomy with versus without
ovarian conservation has similar or different effects on CVD
risk factors, compared with not having surgery and
experiencing a natural menopause.
One approach to addressing these issues is to describe the
prospective changes in cardiovascular risk factors before
and after elective hysterectomy with or without bilateral
oophorectomy in relation to changes in CVD risk factors
that occurred in a comparable period of time before and
after ﬁnal menstrual period (FMP) in women who experi-
enced a natural menopause. This report is based on
cardiovascular risk factor data from SWAN (Study of
Women’s Health across the Nation), a study of a multi-
ethnic sample of women early in the menopausal transi-
tion who were subsequently followed annually. In a prior
SWAN report, we found that the time interval around
FMP due to natural menopause was associated with
substantial increases in low-density lipoprotein cholesterol
(LDL-C) and apolipoprotein (Apo) B (13). We address in
this report whether even larger increases in lipids and other
risk factorsdincluding blood pressure, insulin resistance,
and hemostatic factorsdoccur in women who had
a hysterectomy with or without bilateral oophorectomy
compared those who had a natural menopause. We alsoexamined these patterns with and without consideration of
obesity, given that body mass index (BMI) increased after
bilateral oophorectomy relative to natural menopause in the
present sample (14).Methods
Participants. SWAN is a multi-site community-based
prospective study designed to examine the physical and
psychological health of women as they undergo the meno-
pausal transition. Details of the SWAN design and
recruitment procedures have been reported elsewhere (15).
At baseline, all SWAN participants had an intact uterus and
at least 1 ovary and met the additional eligibility criteria:
42 to 52 years of age, not pregnant, not using reproductive
hormones, and having 1 or more menstrual cycles in the
3 months before the interview. Each site recruited non-
Hispanic Caucasian women as well as women belonging
to a pre-determined racial/ethnic minority group: African-
American women in Pittsburgh, Pennsylvania; Boston,
Massachusetts; Detroit, Michigan; and Chicago, Illinois;
Japanese women in Los Angeles, California; Hispanic
women in Newark, New Jersey; and Chinese women in the
Oakland area of California. Participants were recruited with
established sampling techniques, random digit dialing,
and random sampling from lists of names or household
addresses. Select sites supplemented primary sampling
frames to obtain adequate numbers of racial/ethnic minority
women. Seventy-three percent of the women selected were
contacted and provided information to determine eligibility;
51% (n ¼ 3,302) of eligible women enrolled.
Participants returned to their local site facility annually for
interviewer- and self-administered questionnaires, a fasting
blood draw, and assessments of physical measures. Data
collection for this analysis spanned from 1996 to 2008.
SWAN was approved by the institutional review boards at
each site, and each participant provided written, informed
consent. Data collection ceased at the New Jersey SWAN
site after 2001 for reasons unrelated to scientiﬁc aspects of
the project. Because this resulted in an average length of
follow-up for this site being systematically shorter than that
of any other site, data from this site were excluded from the
current analysis.
Measures andprocedures. MENOPAUSALANDHYSTERECTOMY
STATUS. Menopausal status and the occurrence of hysterec-
tomy and/or oophorectomy were assessed annually in
SWAN. Participants were asked whether they had a
“hysterectomy (an operation to remove your uterus or womb)”
and whether they had 1 or both ovaries removed since the last
study visit. Those who indicated hysterectomy were further
divided into those with and without bilateral oophorectomy,
provided their hysterectomy occurred before becoming
naturally post-menopausal. Medical records were sought for
all women who reported hysterectomy; of the 166 obtained,
all but 1 conﬁrmed hysterectomy and/or oophorectomy.
Women were categorized as naturally post-menopausal if
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193they reported a complete absence of menstrual bleeding in the
previous 12 months and no hysterectomy. The FMP date
or surgery date was based on participant self-report; if FMP
date was unknown, it was set as 12 months before the date
of the annual visit participants were ﬁrst categorized post-
menopausal.
Menopausal status at the annual visit immediately before
the FMP/surgery date of each participant was deﬁned as
pre-menopausal (bleeding in the last 3 months with no cycle
irregularity in the previous 12 months), early peri-
menopausal (bleeding in the last 3 months with some
change in cycle regularity in the last 12 months), late peri-
menopausal (bleeding >3 months ago but within the last
12 months), and unknown (hormone therapy [HT] or other
circumstance interfering with ability to characterize bleeding
patterns) and collapsed for this analysis into 4 categories: pre-
menopausal (pre-menopausal and early peri-menopausal);
peri-menopausal (late peri-menopausal); unknown; and
missing (no menopausal status available for participant,
generally due to nonattendance in the annual visit of the
previous year).
By 2008, a total of 1,952 womendincluding 1,769 women
who reached natural menopause, 77 women who had
a hysterectomywith ovarian conservation, and 106womenwho
had a hysterectomy with bilateral oophorectomydcomprised
the analytic sample. Excluded from the analytic sample were
1,097 womenwho did not report hysterectomy or reach natural
menopause during their participation in the SWAN study;
32 who had a hysterectomy after having been categorized
naturally post-menopausal; 21 who reported hysterectomy in
the presence of known or suspected endometrial, uterine, or
ovarian cancer; 69without BMI data from at least 1 annual visit
post-FMP/surgery (because of its importance as a covariate for
all outcomes and it increased post-surgery [14]); and
131 women from the New Jersey site. The New Jersey site
women did not complete in-person clinic visits after the sixth
annual follow-up and resumed clinic visits at Follow-Up 12.
Thus, this site had an average length of follow-up that is
systematically shorter than that of any other site.
Cardiovascular risk factors. At each annual visit, blood was
drawn in the morning after fasting. All lipid and lipoproteins
were analyzed on ethylenediaminetetraacetic acid–treated
plasma. Total cholesterol and triglycerides were analyzed by
enzymatic methods on a Hitachi 747 analyzer (Boehringer
Mannheim Diagnostics, Indianapolis, Indiana), and high-
density lipoprotein cholesterol (HDL-C) was isolated with
heparin-2Mmanganese chloride. The LDL-Cwas calculated
with the Friedewald equation (16–18). Triglyceride levels and
insulin resistance estimated by homeostasis model of assess-
ment–insulin resistance (HOMA-IR) scores were logged
before analysis. Serum insulin was measured with radioim-
munoassay (DPC Coat-a-count, Los Angeles, California)
procedure and monitored as part of the monthly quality
assurance program by the Diabetes Diagnostic Laboratory at
the University of Missouri. Glucose was measured with
a hexokinase-coupled reaction on a Hitachi 747-200(Boehringer Mannheim Diagnostics). Fibrinogen and Factor
VII were measured in frozen citrated plasma with a clot-based
turbidometric detection system, with Factor VII assay with
Factor VII deﬁcient plasma in preparing the standard curve.
Tissue plasminogen activator antigen (tPA-ag) was measured
in plasma with a double antibody in an enzyme-linked
immunoadsorbent assay (American Diagnostica, Green-
wich, Connecticut), with a human single chain tPA-ag as
a standard calibrated against an international standard
(Hertfordshire, England). Plasminogen activator inhibitor
(PAI)-1 was measured with a solid phased monoclonal
antibody and an enzyme-labeled goal second antiserum
for detection (American Diagnostica). High-sensitivity
C-reactive protein (CRP) was measured with an ultra-
sensitive rate immunonephelometry (Dade-Behring, Mar-
burg, Germany).
Systolic blood pressure (SBP) was manually measured
twice with a minimum 2-min rest period between measures,
with readings taken on the right arm, with the respondent
seated and feet ﬂat on the ﬂoor for at least 5 min before the
measurement. Respondents had not smoked or consumed
any caffeinated beverage within 30 min of blood pressure
measurement. Appropriate cuff size was determined on the
basis of arm circumference. The 2 sequential blood pressure
values were averaged.
Covariates. Covariates included race/ethnicity, educational
attainment, menopausal status, and age the year before
FMP or surgery as well as annual measurements of physical
activity, smoking status, self-rated health, myocardial
infarction, stroke, HT use, BMI, and antidepressant,
insulin, antihypertensive, lipid-lowering, and heart medica-
tion use. Race/ethnicity and educational level were self-
reported in the screening interview. Age was calculated
from participant date of birth and date of FMP or surgery.
Physical activity was assessed with the Kaiser Physical
Activity Survey (19), an adaptation of the Baecke physical
activity questionnaire (20) at baseline and annual Follow-Up
Visits 3, 5, and 6. A sum score was derived from responses to
questions about physical activity during sports/exercise,
household/caregiving tasks, and daily routine in the previous
year. Current smoking status was self-reported at each
annual visit. Self-rated health was assessed at each annual
visit by response to the following question: “In general,
would you say your health is excellent, very good, good, fair,
or poor?” (21). Responses were categorized into 2 categories,
with responses of “excellent” and “very good” collapsed into
1 category, and “good,” “fair,” and “poor” collapsed into
another category. Medication use and new medical diag-
noses were self-reported at each annual visit. The BMI was
measured at each visit by a trained technician.
Statistical analyses. Site, race/ethnicity, age at FMP/
surgery, educational attainment, menopausal status the year
before FMP/surgery, and reported myocardial infarction or
stroke were included as covariates in ﬁnal models on the
basis of a priori decisions. Annual insulin use for outcomes
related to glucose metabolism, annual hypertensive
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annual lipid-lowering medication use for outcomes related
to dyslipidemia, and annual heart medications related to
hemostatic and inﬂammatory factors and blood pressure
were also included a priori. Preliminary analyses were
conducted to assess independent associations between
annual observations of antidepressant use, HT use, self-
rated health, smoking status, and physical activity with
outcomes with hierarchical linear regression. These time-
varying covariates were retained in ﬁnal models if they
were associated with the outcomes in otherwise unadjusted
models at p < 0.05.
Baseline characteristics of women with natural meno-
pause, women with hysterectomy with ovarian conservation,
and women with hysterectomy with bilateral oophorectomy
were compared with chi-square or Fisher exact test for
categorical variables and analysis of variance for continuous
variables (without covariates) with SPSS (version 17 for
Windows, Rel 17.0.0, 2008, SPSS, Chicago, Illinois).
Piecewise hierarchical linear growth models were used to
estimate the mean annual rate of change in CVD risk factors
from baseline to the index visit, which was the ﬁrst annual
visit after FMP or surgery, and from the index visit to end of
follow-up, with annual observations nested within women
(HLM for Windows, version 6.08, 2010, Scientiﬁc Software
International, Lincolnwood, Illinois). Note that the time
between FMP or surgery and the index visit was a covariate.
Hierarchical linear modeling was used, due to its utility in
accounting for the dependence of repeated, correlated
observations within individuals. Piecewise hierarchical linear
growth models allowed for the possibility of different mean
growth trajectories before and after FMP or surgery (22).
The intercept was set at the index visit and modeled as
a function of group status with covariates: site; race/
ethnicity; educational attainment; age at FMP or surgery;
menopausal status at the visit before FMP or surgery; and
elapsed time between FMP or surgery and index visit and
elapsed time between index visit and end of observations. An
interaction between hysterectomy status (hysterectomy with
ovarian conservation or hysterectomy with bilateral oopho-
rectomy, with natural menopause set as the referent) and
each time variable examined whether either hysterectomy
status group differed signiﬁcantly from the natural meno-
pause group at the index visit or the annual changes before or
after. For the referent group, the estimate refers to whether
the level differs from 0. All predictors and covariates were
entered simultaneously in the ﬁnal multivariable models
presented in the tables. For all analyses, p values <0.05
(2-tailed) were considered statistically signiﬁcant. Tables
present the results without adjustment for BMI. When
adjustments for BMI changed the pattern of results, it is
noted in the Results section.
To assess potential interactions between hysterectomy status
and race/ethnicity, a secondary analysis was performed in
a sample restricted to only African-American and Caucasian
women to determine whether potential increases in theseCVDrisk factors after hysterectomy with or without oophorectomy
were greater among African-American compared with
Caucasian women. Other groups represented in the SWAN
study were not included, due to their very low numbers of
hysterectomy with or without bilateral oophorectomy. The
sample for this secondary analysis included 1,422 African-
American and Caucasian women who reached natural meno-
pause, 71 women who had a hysterectomy with ovarian
conservation, and 88 women who had a hysterectomy with
bilateral oophorectomy. Models were otherwise identical to
those described in the preceding text.Results
Characteristics of analytic sample. Compared with the
women who were excluded from the analysis, women in the
analytic sample were older (46.3  2.6 years vs. mean
45.2  2.7 years, p < 0.001), more educated (46.5% vs.
37.3% college or post-college, p < 0.001), reported better
self-rated health (61.3% vs. 52.6% excellent/very good
health, p< 0.001), had higherHDL-C (61.0 16.5 vs. mean
54.7  16.0, p < 0.001), and had lower BMI (28.0  7.3 vs.
28.8  7.1, p < 0.01), HOMA-IR scores (3.3  4.0 vs.
5.0  7.0, p < 0.01 on the basis of logged values), and SBP
(117.8  17.3 vs. 124.0  15.6, p < 0.001) at baseline. Of
the 183 women in the 2 surgery groups, 140 had docu-
mented medical records with regard to diagnosis. The most
common preoperative symptoms and diagnoses in the
available medical records were suspected or diagnosed
uterine ﬁbroids (75.7%), suspected or diagnosed menor-
rhagia (58.6%), and chronic pelvic pain (25.7%). Suspected
or diagnosed ﬁbroids accompanied the presentation of
menorrhagia (85.4%) and chronic pelvic pain (83.3%) in this
sample.
Participants were followed for up to 11 years after study
entry, with observations from up to 9 years before and after
FMP or surgery and a mean  SD number of exams/woman
being 10.78  0.90, with 4.71  2.33 on average after FMP
or surgery. On average women reported HT use after FMP
or surgery at 0.72  1.58, 1.22  1.75, and 3.42  2.97
visits for natural menopause, hysterectomy with ovarian
conservation, and hysterectomy with bilateral oophorectomy
groups, respectively (p < 0.001). The proportion of visits on
HT throughout the study before and after FMP or surgery
for these groups were, on average, 0.14  0.34, 0.22  0.29,
and 0.57  0.36, p < 0.001.
Women who subsequently reported hysterectomy with or
without oophorectomy were more likely to be African-
American and younger (Table 1). The tPA-ag levels were
elevated at study entry among women who later had
hysterectomy with bilateral oophorectomy, whereas BMI,
Factor VIIc levels, and use of lipid-lowering medications
were higher at study entry among women who later had
hysterectomy with ovarian conservation, as compared with
women with naturally occurring menopause. No other risk
factors differed by FMP/surgery status.
Table 1 Characteristics of Women in Analytic Sample
Total
(n ¼ 1,952)
Natural Menopause
(n ¼ 1,769, 90.6%)
Hysterectomy With
Ovarian Conservation
(n ¼ 77, 3.9%)
Hysterectomy With
Bilateral Oophorectomy
(n ¼ 106, 5.4%)
Group ANOVA
p Values
Race/ethnicity <0.001
White 946 (48.5) 870 (49.2) 32 (41.6) 44 (41.5)
African-American 615 (31.5) 528 (29.8) 40 (51.9)* 47 (44.3)*
Chinese 180 (9.2) 172 (9.7) 0 (0) 8 (7.5)
Japanese 211 (10.8) 199 (11.2) 5 (6.5) 7 (6.6)
Menopausal status at visit before FMP/surgery <0.001
Pre-menopausal 415 (21.3) 323 (18.3) 44 (57.1)* 48 (45.3)
Peri-menopausal 847 (43.4) 840 (47.5) 2 (2.6)* 5 (4.7)*
Unknown 309 (15.8) 283 (16.0) 9 (11.7) 17 (16.0)*
Missing 381 (19.5) 323 (18.3) 22 (28.6) 36 (34.0)
Education 0.25
High school 400 (20.6) 363 (20.6) 13 (16.9) 24 (22.6)
Some college 634 (32.7) 565 (32.1) 26 (33.8) 43 (40.6)*
College 907 (46.7) 830 (47.2) 38 (49.4) 39 (36.8)
Baseline self-rated health 0.10
Excellent or very good 426 (22.0) 377 (21.5) 24 (31.6)* 25 (23.8)
Good/fair/poor 1,511 (78.0) 1,379 (78.5) 52 (68.4) 80 (76.2)
Baseline antidepressant use 0.55
Yes 172 (8.8) 152 (8.6) 9 (11.8) 11 (10.4)
No 1,776 (91.2) 1,614 (91.4) 67 (88.2) 95 (89.6)
Baseline lipid-lowering medication use 0.03
Yes 20 (1.0) 15 (0.8) 4 (5.3)* 1 (0.9)
No 1,927 (99.0) 1,750 (99.2) 72 (94.7) 105 (99.1)
Baseline heart medication use 0.33
Yes 53 (2.7) 45 (2.5) 3 (3.9) 5 (4.7)
No 1,899 (97.3) 1,724 (97.5) 74 (96.1) 101 (95.3)
Baseline current smoker 0.45
Yes 311 (16.0) 283 (16.1) 15 (19.5) 13 (12.6)
No 1,627 (84.0) 1,475 (83.9) 62 (80.5) 90 (87.4)
Baseline past stroke/MI 0.70
Yes 17 (0.9) 16 (0.9) 0 (0.0) 1 (1.0)
No 1,886 (99.1) 1,709 (99.1) 75 (100.0) 102 (99.0)
Baseline
Age (yrs) 46.31  2.61 46.41  2.59 44.94  2.55* 45.66  2.62* <0.001
BMI (kg/m2) 27.95  7.32 27.77  7.28 30.12  7.90* 29.47  7.32 <0.01
Physical activity score 7.74  1.77 7.75  1.77 7.73  2.00 7.58  1.65 0.67
LDL-C (mg/dl) 115.44  31.38 115.19  31.24 122.08  31.01 114.79  33.59 0.18
HDL-C (mg/dl) 57.28  14.18 57.52  14.25 55.22  13.93 54.78  13.02 0.07
ApoB (mg/dl) 110.33  26.68 110.20  29.57 115.87  30.68 108.54  30.73 0.22
ApoA1 (mg/dl) 151.63  24.18 151.96  24.11 148.29  25.06 148.55  24.54 0.17
Triglycerides (mg/dl) 109.24  78.36 109.03  80.09 111.05  65.35 111.41  54.49 0.38y
HOMA-IR 2.94  5.92 2.94  6.14 3.01  2.43 3.03  3.71 0.11y
SBP (mm Hg) 117.82  17.32 117.57  17.25 118.16  18.17 121.88  17.56 0.06
tPA-ag (ng/ml) 8.17  7.05 7.95  5.69 8.44  4.50 11.82  19.05* <0.001
PAI-1 (ng/ml) 25.86  39.20 25.80  39.00 21.35  26.17 30.37  49.91 0.47
Factor VIIc (mg/dl) 127.81  44.18 126.52  32.59 155.70  139.65* 125.13  35.59 <0.01
CRP (mg/l) 3.70  6.17 3.62  6.16 3.94  4.13 4.89  7.51 0.11
Age at FMP/surgery, yrs 51.44  2.73 51.72  2.53 48.00  2.83* 49.25  3.05* <0.001
Values are n (%) or mean  SD. *Group differs signiﬁcantly (p < 0.05) from natural menopause in post hoc analyses. yThe p value from logged analyses.
ANOVA ¼ analysis of variance; Apo ¼ apolipoprotein; BMI ¼ body mass index; CRP ¼ C-reactive protein; FMP ¼ ﬁnal menstrual period; HDL-C ¼ high density lipoprotein cholesterol;
HOMA-IR ¼ homeostasis model of assessment–insulin resistance; LDL-C ¼ low density lipoprotein cholesterol; MI ¼ myocardial infarction; PAI ¼ plasminogen activator inhibitor; SBP ¼ systolic blood
pressure; tPA-ag ¼ tissue plasminogen activator antigen.
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195Lipid changes. At the time of the index visit, women with
hysterectomy with ovarian conservation had higher LDL-C
and tended to have higher ApoB levels (which wassigniﬁcant when adjusted for BMI), whereas women with
hysterectomy with bilateral oophorectomy had higher
triglyceride levels, relative to the natural post-menopausal
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196women (Table 2) (Figure 1 shows the covariate-adjusted
means (95% conﬁdence intervals) on the basis of predicted
values from linear regression models within each year.) The
LDL-C, triglycerides, and ApoA1 levels increased annually
before and after FMP, whereas HDL-C decreased annually
after FMP. The ApoB increased before FMP and nonsig-
niﬁcantly declined after FMP. The change in these factors
was similar before and after surgery compared with before
and after FMP, with 2 exceptions. The increase in ApoA1
levels was larger, with a modest decline in triglyceride levels
before surgery in women with hysterectomy with ovarian
conservation, compared with those who became naturally
post-menopausal. Further adjustments for BMI did not alter
the results.
Other cardiovascular risk factors. At the index visit,
groups did not differ in HOMA-IR, SBP, tPA-ag, Factor
VIIc, or CRP levels (Table 3). From study entry to FMP,
women increased annually in SBP, tPA-ag, and Factor VIIc
and declined annually in PAI-1 and CRP. These changes
were similar to those experienced by women from baseline to
surgery, except that tPA-ag decreased annually in women
who had a hysterectomy with ovarian conservation, and
CRP levels increased annually more in the women who
subsequently had a hysterectomy with bilateral oophorec-
tomy (Table 3). After FMP, HOMA-IR increased annually,
and PAI-1 declined. After surgery the changes were similar
to those experienced by the natural menopause group.
Further adjustments for BMI did alter the results
somewhat for tPA-ag and CRP: after FMP, tPA-ag
increased annually (estimate [SE] ¼ 0.74 [0.35] p ¼
0.04), whereas it declined annually after either hysterectomy
with ovarian conservation (estimate ¼ 0.14 [0.43], p ¼
0.04) or after hysterectomy with bilateral oophorectomy
(estimate ¼ 0.13 [0.47], p ¼ 0.06). The CRP levels after
hysterectomy with ovarian conservation declined annually
(estimate ¼ 0.24 [0.17], p ¼ 0.04), relative to after FMP
(estimate ¼ 0.11 [0.08]).
There were no signiﬁcant effects of ethnicity and change
in CV risk factors before and after FMP or surgery. In other
words, the impact of hysterectomy with or without oopho-
rectomy in relation to FMP did not differ between African
Americans and Caucasians.
Discussion
The objective of the present paper was to compare the
annual CVD risk factor changes that occur in midlife
women before and after natural menopause or hysterectomy
with or without ovarian conservation. The inﬂuence of
natural menopause and hysterectomy with or without
ovarian conservation was similar for HDL-C, LDL-C,
ApoB, HOMA-IR, SBP, PAI-1, and Factor VIIc over
time. Several CVD risk factor changes did differ during the
intervals before and after hysterectomy, compared with the
changes before and after FMP but not in a pattern sug-
gesting increasing cardiovascular risk after hysterectomy.
Figure 1 Lipids Annual Means
Covariate-adjusted means (95% conﬁdence interval) at the time of surgery and before and after surgery compared with values at the time of ﬁnal menstrual period (FMP) and
before and after FMP on the basis of predicted values from adjusted linear regression models within each year. Slopes before and after surgery compared with slopes before and
after FMP were identical, except for a steeper slope for ApoA1 before having hysterectomy with ovarian conservation (p ¼ 0.03). Abbreviations as in Table 1.
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197Before hysterectomy with ovarian conservation, triglycerides
and tPA changes declined and ApoA1 increased, compared
with the changes before natural menopause, suggesting a
lower risk trajectory among these women pre-surgically.
Before hysterectomy with bilateral oophorectomy, CRP
increases were greater than before a natural menopause, but
no differences occurred after surgery, compared with after
FMP. The absence of effects for the group that should
presumably be at the highest riskdwomen who had a
hysterectomy with bilateral oophorectomydmight be due to
the inﬂuence of HT use, although some evidence points to
elevated CRP being associated with HT (23). Thus, weconclude that hysterectomy with or without bilateral
oophorectomy does not introduce a substantial increase in
cardiovascular risk factors among midlife women.
On the surface, our results differ from those of the
Women’s Health Initiative. In that study, elderly women
who had reported having a hysterectomy, regardless of
oophorectomy status, had at baseline higher levels of CVD
risk factors (8) and a higher proportion of hypertension,
diabetes, high cholesterol, and obesity, compared with
women who had natural menopause. There are likely to be
a number of reasons for the differences. Our focus was on
risk factor levels, adjusted for medications for hypertension,
Table 3 Regression Coefﬁcients and Their p Values From Fully Adjusted Models for Other Cardiovascular Risk Factor Levels at Index Visit and Changes Before and After Index Visit
(log) HOMA-IR SBP TPA-ag PAI-1 Factor VIIc CRP
Coefﬁcient (SE) p Value Coefﬁcient (SE) p Value Coefﬁcient (SE) p Value Coefﬁcient (SE) p Value Coefﬁcient (SE) p Value Coefﬁcient (SE) p Value
Mean at index visit
Natural menopause (referent) 0.30 (0.02) d 111.58 (1.23) d 8.04 (0.84) d 24.68 (3.14) d 129.77 (3.06) d 2.97 (0.54) d
Hysterectomy with ovarian conservation 0.32 (0.04) 0.58 112.56 (2.06) 0.63 7.68 (0.78) 0.64 21.40 (4.83) 0.50 154.08 (21.56) 0.26 3.77 (0.83) 0.33
Hysterectomy with bilateral
oophorectomy
0.29 (0.03) 0.78 114.14 (1.66) 0.12 8.23 (1.09) 0.86 26.15 (4.80) 0.76 131.76 (5.19) 0.70 4.20 (0.77) 0.11
Mean annual rate of change from baseline
to index visit
Natural menopause (referent) 0.00 (0.00) 0.06 0.40 (0.12) <0.001 0.24 (0.08) <0.01 1.94 (0.57) <0.001 1.27 (0.39) <0.01 0.15 (0.06) 0.02
Hysterectomy with ovarian conservation 0.00 (0.02) 0.88 0.38 (1.19) 0.51 0.39 (0.20) <0.01 1.73 (1.92) 0.92 7.41 (6.40) 0.34 0.97 (1.33) 0.53
Hysterectomy with bilateral
oophorectomy
0.00 (0.01) 0.86 1.04 (0.61) 0.30 0.40 (0.30) 0.60 0.27 (1.90) 0.38 0.80 (1.97) 0.29 0.58 (0.25) <0.01
Mean annual rate of change after
index visit
Natural menopause (referent) 0.02 (0.00) <0.001 0.01 (0.10) 0.92 0.27 (0.22) 0.23 2.54 (0.53) <0.001 0.33 (0.59) 0.58 0.14 (0.08) 0.07
Hysterectomy with ovarian conservation 0.01 (0.01) 0.42 0.02 (0.34) 0.98 0.15 (0.27) 0.67 1.67 (1.81) 0.63 8.27 (9.31) 0.40 0.19 (0.25) 0.18
Hysterectomy with bilateral
oophorectomy
0.02 (0.01) 0.88 0.02 (0.36) 0.93 0.18 (0.36) 0.21 3.21 (1.72) 0.69 0.50 (2.22) 0.94 0.03 (0.22) 0.61
Models adjusted by site, race/ethnicity, educational attainment, age at FMP or surgery, menopausal status at visit before FMP or surgery, elapsed time between index visit and FMP or surgery (all time-invariant), and stroke or MI, heart medication use (SBP, tPA, PAI-1, factor
VIIc), physical activity, antidepressant use (HOMA-IR, PAI-1, Factor VIIc, CRP), hormone therapy use, smoking status, and antihypertensive medication use (SBP) (time-varying). All covariates entered simultaneously. The p values for natural menopause (referent) refer to
signiﬁcant difference from 0; p values for hysterectomy with ovarian conservation and hysterectomy with bilateral oophorectomy refer to signiﬁcant difference from natural menopause.
Abbreviations as in Table 1.
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199diabetes, and high cholesterol. In the Women’s Health
Initiative, CVD risk factor data collection had typically
occurred many years after surgery, whereas in the present
study the risk factor, surgical status, and menstrual cycle
information were collected annually and concurrently for
11 years. Our analyses were restricted to elective surgery, and
we excluded surgery due to cancer because of treatment and
disease effects, whereas the Women’s Health Initiative did
not exclude women with speciﬁc causes for the surgery.
Finally, the frequency and reasons for surgical menopause
are undoubtedly different for the 2 cohorts, because of
changes in recommendations with regard to hysterectomy
over the decades.
Study limitations. Our study ﬁndings are limited by
a number of factors. First, the sample was composed of pre-
menopausal women who were initially 42 to 52 years of age,
all of whom had a uterus and at least 1 ovary at entry.
Perhaps they were not young enough, because bilateral
oophorectomy might have a greater impact on CVD risk if
the surgery is performed at younger ages (24), when the
decline in ovarian hormones is more pronounced. Given that
we could evaluate surgeries only occurring after study entry,
restricting the range in age and time of surgery in the
sample, we could not evaluate the inﬂuence of age at surgery
on our results. Second, there were relatively few cases of
hysterectomy and bilateral oophorectomy. Many women
who have elective hysterectomy are entering the peri-
menopause and would not have been eligible initially for
the cohort. Thus, the SWAN sample is not typical of
the general population of midlife women, many of whom
have had a hysterectomy or oophorectomy by midlife. Giv-
en the large number of risk factors and comparisons tested,
the few signiﬁcant associations observed might be due to
chance. Finally, the study could not address the impact of
surgery on clinical events, because the follow-up ended
before the high-risk period in women (i.e., above 65 years
of age).
The study has a number of strengths. It is composed of a
large, well-characterized sample of midlife women. Detailed
data were collected annually with women having an average
of over 10 assessments. The analytic approach compared
annual changes in CVD risk before and after FMP or
surgery and was robust to missing data. A large number of
covariates, including use of medications known to inﬂuence
risk factors and HT, were included. Thus, it is the only study
that has carefully tracked prospective changes in CVD risk
factors relative to FMP or surgical menopause.
Conclusions
Although women in midlife experienced signiﬁcant increases
in CVD risk, the women who had surgical menopause in
their 40s and 50s were not at any greater risk for increases in
CVD risk factors compared with women who had a natural
menopause. These results should provide reassurance to
women and their clinicians that hysterectomy with orwithout ovarian conservation in midlife is not likely to
substantially accelerate the CVD risk of women.Acknowledgments
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APPENDIX
For a list of the participating centers and investigators, please see the
online version of this article.
